You are viewing the site in preview mode

Skip to main content

Table 2 Results obtained by using BEV in MGs

From: Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas

  n (%)
Objective responses
 Complete response (CR) 1 (5.9)
 Partial response (PR) 7 (41.2)
 Stable disease (SD) 3 (17.6)
 Progressive disease (PD) 6 (35.3)
 Overall response rate (ORR) 8 (47.1)
 Disease control (DC) 11 (64.7)
Survival data
 6 months-PFS, % 41.2
 12 months-PFS, % 29.4
 Median PFS, months (range) 5 (1-40)
 6 months-OS, % 58.8
 12 months-OS, % 35.3
 Median OS, months (range) 8.3 (1-45)
  1. PFS progression free survival, OS overall survival